Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced today the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be met. PEG-INTRON (peginterferon alpha-2b), is approved for the treatment of Hepatitis C and is marketed worldwide by Schering-Plough Corporation (SGP).

Speaking on behalf of DRC, Paul Kirkconnell, Managing Director, said: "DRC is very pleased to be working with Enzon Pharmaceuticals. We believe that PEG- INTRON is one of the most advanced medications to treat Hepatitis C on the market today." Kirkconnell added, "With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon."

About PEG-INTRON(R)

PEG-INTRON is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON(R) A, which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's license agreement with Schering-Plough, Schering-Plough holds an exclusive worldwide license to PEG-INTRON, and Enzon receives royalties on worldwide sales of PEG-INTRON. Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON. Enzon designed PEG-INTRON to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. PEG-INTRON is marketed worldwide by Schering-Plough and its affiliates.

About Drug Royalty Corporation, Inc. (DRC)

Drug Royalty Corporation ("DRC") is a privately held investment management company, focused on the healthcare industry, with over $1 billion under management. DRC currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing roya
'/>"/>

SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare AB ... to acquire YouMedical Group BV ("YouMedical"), a Dutch OTC ... total annual sales of approximately EUR 16 million, with ... "Our ambition is to build a leading ... step toward that goal. YouMedical gives us a stronger ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... There’s a ... Minerva is the first commercially available new FDA approved system in the last ... rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Global & USA ... offering. The highly awaited US Biosimilar market ... highly awaited filigrastim biologic, Zarxio. How will the global ... The author reveals that biosimilars could save the US ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... , CRANBURY, N.J., Aug. 4 Palatin ... that it has received a Notice of Allowance from the ... Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs." Allowed claims ... peptide receptor A (NPRA), including PL-3994, Palatin,s lead heart failure ...
... Thin-film zeolite membranes with tiny, molecule-sized pores are one ... in industrial separations, a group of academic researchers is ... magazine, the group says the membranes, ability to separate ... the zeolite to rapid thermal processing (RTP). By heating ...
... , ROCKVILLE, Md., Aug. 3 Human Genome ... closing of its public offering of 26,697,250 newly issued shares ... of $14.00 per share, which includes 3,482,250 shares sold upon ... shares. The net proceeds to the Company from the ...
Cached Biology Technology:Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 2Rapid heating prepares energy-saving zeolite for greater role in industrial separations 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 4Human Genome Sciences Announces Closing of Public Offering 2Human Genome Sciences Announces Closing of Public Offering 3
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... at how much you can learn from a plant. In ... a Michigan State University professor and a colleague discuss why if ... to plants for any number of valuable lessons. "Metabolism of ... Last, an MSU professor of biochemistry and molecular biology. "As the ...
... scientists have added to a growing list of types ... the genetic code, they have found the short strands ... from Howard Hughes Medical Institute (HHMI) scientists suggests those ... engine, capable of querying the entire history of a ...
... prefer inexpensive, traditional stoves for cooking over modern ones ... in the Proceedings of the National Academy of ... that indoor smoke from the traditional stoves is harmful, ... spoiled food (66 percent). Still, Bangladeshi women opted for ...
Cached Biology News:Scientists urge new approaches to plant research 2Short stretches of piRNA evaluate cells' genetic history 2Short stretches of piRNA evaluate cells' genetic history 3Bangladeshi women prefer pollution-causing cookstoves 2
...
...
Collected from sexually mature mice....
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Biology Products: